Follows people with lupus in Saudi Arabia over time through a prospective registry
Follows adults with systemic lupus erythematosus to learn how the disease appears and progresses.
Plain-language title generated from the registry record
Registry title: National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
Key facts
- Where
- Riyadh, Saudi ArabiaSee the site
Where in Saudi Arabia
- King Saud University Medical CityRiyadh, Saudi ArabiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- King Saud University
- Trial code
- NCT04604990
- Record updated
- 1 September 2021
- Original description
SLE disease in Saudi Arabia is yet not well defined especially in a population with high consanguinity and high inbreeding coefficient . Up until now, there has been no prospective cohort study for SLE patients in Saudi Arabia. As a result, current published literature is focused on retrospective chart reviews which are subjected to many forms of bias. so the investigator proposed this prospective registry which will follow open cohort study design aiming to provide better understanding of disease presentation, course and outcomes especially if complemented by detailed immunological, molecular, genetic and microbiome data.Read full original descriptionShow less
National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
SLE disease in Saudi Arabia is yet not well defined especially in a population with high consanguinity and high inbreeding coefficient . Up until now, there has been no prospective cohort study for SLE patients in Saudi Arabia. As a result, current published literature is focused on retrospective chart reviews which are subjected to many forms of bias. so the investigator proposed this prospective registry which will follow open cohort study design aiming to provide better understanding of disease presentation, course and outcomes especially if complemented by detailed immunological, molecular, genetic and microbiome data.
Inclusion: Adult patients defined as age greater than 18 years old; Patients should fulfil one of the following classification criteria for SLE (ACR, SLICC or ACR/EULAR criteria); No restriction on time of diagnosis.
Exclusion: Patients who don't fulfil classification criteria mentioned above.